Loading...

BioDelivery Sciences International, Inc.

BDSI•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$5.59
$-0.00(-0.09%)

BioDelivery Sciences International, Inc. (BDSI) Stock Overview

Explore BioDelivery Sciences International, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 68.6/100

Key Financials

Market Cap577.1M
P/E Ratio6.80
EPS (TTM)$0.82
ROE0.57%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$5.78

BDSI Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of BioDelivery Sciences International, Inc. (BDSI) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $5.78.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 6.80 and a market capitalization of 577.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for BDSIStats details for BDSI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for BDSIAnalyst Recommendations details for BDSI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.

CEO

Herm Cukier

Employees

200

Headquarters

4131 Parklake Ave Ste 225, Raleigh, NC

Founded

2002

Frequently Asked Questions

;